 |
Which patient segments should we explore to establish 'proof of concept' in Phase II trials |
|
Which treatment(s) should we consider as Standard of Care from a Payer perspective? Now, and in the future? How do we determine what is 'emerging' Standard of Care |
|
How do we design our Phase III clinical programme to meet the evidence requirements for national Payers to achieve target pricing, reimbursement and willingness to fund in target patient segments |
|
What clinical trial design will enable us to conduct network meta-analyses and multiple treatment comparisons in a robust manner |
|
How should we manage the development of sequential indications to maintain Payer support for the brand through the life cycle as budget impact increases |
|
What price corridor should we establish to ensure both reimbursement and funding in target patient segments across multiple markets |
|
How do we demonstrate value in a Value Based Pricing process |
|
Which Payer customers do we need to support us at national and local level? What are their decision making criteria and how do we satisfy them |
|
How should we develop, test and communicate a robust and compelling market access Value Proposition and Value Messages to ensure acceptance at national, regional and local level |
|
How should we adapt the Value Proposition to satisfy local country requirements |
|
What approach do we adopt for the development of our Global Value Dossier to ensure affiliates receive necessary support to build their P&R submissions |
|
What is the best method of economic modelling to demonstrate the value of our brand for health technology appraisal |
|
How should we train our market access Customer-facig teasm to build both their confidence and competence to deliver a compelling Value Proposition to achieve successful access |
